The present invention provides a monomeric insulin analog formulation stabilized against aggregation in which the buffering agent is either TRIS or arginine. The stable formulations of the present invention are useful for treating diabetes, and are particularly advantageous in treatment regimes requ
The present invention provides a monomeric insulin analog formulation stabilized against aggregation in which the buffering agent is either TRIS or arginine. The stable formulations of the present invention are useful for treating diabetes, and are particularly advantageous in treatment regimes requiring lengthy chemical and physical stability, such as, in continuous infusion systems.
대표청구항▼
1. A method for treating diabetes comprising administering an effective dose of a solution formulation, the solution formulation comprisinga physiologically tolerated buffer selected from the group consisting of 2-amino-2-hydroxymethyl-1,3-propanediol and arginine; a monomeric insulin analog; zinc;
1. A method for treating diabetes comprising administering an effective dose of a solution formulation, the solution formulation comprisinga physiologically tolerated buffer selected from the group consisting of 2-amino-2-hydroxymethyl-1,3-propanediol and arginine; a monomeric insulin analog; zinc; a phenolic preservative; and an isotonicity agent, wherein the solution formulation is administered using a continuous infusion system. 2. The method of claim 1, wherein the solution formulation is a stable formulation.3. The method of claim 1, wherein the buffer is 2-amino-2-hydroxymethyl-1,3-propanediol.4. The method of claim 1, wherein the monomeric insulin analog is AspB28-human insulin.5. The method of claim 1, wherein the monomeric insulin analog is LysB28ProB29-human insulin.6. The method of claim 1, wherein the pH of the formulation is between pH 7.0 and pH 8.0 when measured at a temperature of 22° C.7. The method of claim 1, wherein the concentration of the monomeric insulin analog is between about 1.2 mg/mL and about 50 mg/mL.8. The method of claim 7, wherein the concentration of the monomeric insulin analog is between about 3.0 mg/mL and about 35 mg/mL.9. The method of claim 4, wherein the concentration of AspB28-human insulin is between about 1.2 mg/mL and about 50 mg/mL.10. The method of claim 9, wherein the concentration of AspB28-human insulin is between about 3.0 mg/mL and about 35 mg/mL.11. The method of claim 5, wherein the concentration of LysB28ProB29-human insulin is between about 1.2 mg/mL and about 50 mg/mL.12. The method of claim 11, wherein the concentration of LysB28ProB29-human insulin is between about 3.0 mg/mL and about 35 mg/mL.13. A method for treating hyperglycemia comprising administering an effective dose of a solution formulation, the solution formulation comprisinga physiologically tolerated buffer selected from the group consisting of 2-amino-2-hydroxymethyl-1,3-propanediol and arginine; a monomeric insulin analog; zinc; a phenolic preservative; and an isotonicity agent, wherein the solution formulation is administered using a continuous infusion system. 14. The method of claim 13, wherein the solution formulation is a stable formulation.15. The method of claim 13, wherein the buffer is 2-amino-2-hydroxymethyl-1,3-propanediol.16. The method of claim 13, wherein the monomeric insulin analog is AspB28-human insulin.17. The method of claim 13, wherein the monomeric insulin analog is LysB28ProB29-human insulin.18. The method of claim 13, wherein the pH of the formulation is between pH 7.0 and pH 8.0 when measured at a temperature of 22° C.19. The method of claim 13, wherein the concentration of the monomeric insulin analog is between about 1.2 mg/mL and about 50 mg/mL.20. The method of claim 19, wherein the concentration of the monomeric insulin analog is between about 3.0 mg/mL and about 35 mg/mL.21. The method of claim 16, wherein the concentration of AspB28-human insulin is between about 1.2 mg/mL and about 50 mg/mL.22. The method of claim 21, wherein the concentration of AspB28-human insulin is between about 3.0 mg/mL and about 35 mg/mL.23. The method of claim 17, wherein the concentration of LysB28ProB29-human insulin is between about 1.2 mg/mL and about 50 mg/mL.24. The method of claim 23, wherein the concentration of LysB28ProB29-human insulin is between about 3.0 mg/mL, and about 35 mg/mL.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (11)
Thurow Horst (Kelkheim DEX), Aqueous protein solutions stable to denaturation.
Anderson ; Jr. James H. (Carmel IN) De Felippis Michael R. (Indianapolis IN) Frank Bruce H. (Indianapolis IN) Havel Henry A. (Indianapolis IN), Insulin analog formulations.
Bakaysa Diane L. (Indianapolis IN) Brems David N. (Indianapolis IN) Frank Bruce H. (Indianapolis IN) Havel Henry A. (Indianapolis IN) Pekar Allen H. (Indianapolis IN), Insulin analog formulations.
Chance Ronald E. (19303 Flippin Rd. Westfield IN 46074) DiMarchi Richard D. (3815 Wolf Creek Cir. Carmel IN 46032) Frank Bruce H. (8025 Claridge Rd. Indianapolis IN 46260) Shields James E. (17808 Gra, Insulin analogs modified at position 29 of the B chain.
Backstrom Kjell Goran Erik (Lund SEX) Dahlback Carl Magnus Olof (Lund SEX) Edman Peter (Bjarred SEX) Johansson Ann Charlotte Birgit (Lund SEX), Therapeutic preparation for inhalation.
DiPerna, Paul M.; Brown, David; Rosinko, Mike; Kincade, Dan; Michaud, Michael; Nadworny, John; Kruse, Geoffrey A.; Ulrich, Thomas R., Infusion pump system with disposable cartridge having pressure venting and pressure feedback.
DiPerna, Paul M.; Brown, David; Rosinko, Mike; Kincade, Dan; Michaud, Michael; Nadworny, John; Kruse, Geoffrey A.; Ulrich, Thomas R., Infusion pump system with disposable cartridge having pressure venting and pressure feedback.
Verhoef, Erik T.; DiPerna, Paul M.; Rosinko, Mike; Williamson, Mark; Kruse, Geoffrey A.; Ulrich, Thomas R.; Lamb, Phil; Saint, Sean; Michaud, Michael; Trevaskis, William, Infusion pump system with disposable cartridge having pressure venting and pressure feedback.
Yang, Tzung-Horng; Vaughn, Daniel Edward; Labarre, Michael James; Caster, Christopher L.; Nicol, Francois; Kim, Donghyun, Stable formulations of a hyaluronan-degrading enzyme.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.